Navigation Links
In the Psoriasis Drug Market, Continued Uptake of Janssen's Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
Date:10/21/2013

BURLINGTON, Mass., Oct. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the psoriasis drug market will experience substantial growth over the next decade as sales increase from $5.5 billion in 2012 to nearly $9.2 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Psoriasis finds that the continued uptake of Janssen's interleukin 12/23 inhibitor Stelara, which is expected to experience first-line biologic use ahead of the TNF-alpha inhibitors in the second half of the 2012-2022 forecast period, will drive sales growth. Stelara is forecast to achieve sales of $2.2 billion in 2022, accounting for 24 percent of total psoriasis sales. The launches and uptake of several emerging agents—the IL-17 inhibitors (Novartis's secukinumab, Eli Lilly's ixekizumab, and Amgen/AstraZeneca/Kyowa Hakko Kirin's brodalumab) as well as Pfizer's Janus kinase inhibitor Xeljanz—will also drive sales through 2022. 

The findings also reveal that the TNF-alpha inhibitors, particularly AbbVie/Eisai's Humira, which has displaced Amgen/Stiefel/Pfizer/Takeda's Enbrel as the preferred first-line biologic, will continue to dominate as first-line biologic agents in the first half of our forecast. However, dermatologists will increasingly turn to Stelara for their biologic-naive patients, owing to the drug's favorable risk/benefit profile. This is supported by years of postmarketing safety data and will drive sales in the second half of the 2012-2022 forecast period. Beginning in 2014, the TNF-alpha inhibitors and Stelara will experience competition from emerging biologics and oral agents with novel mechanisms of action. Although concerns about their undefined safety profiles will restrict uptake initially, the emerging IL-17 inhibitors, Xeljanz, and Merck's IL-23 inhibitor MK-3222, will increase competition within the TNF-alpha-refractory space. Celgene's oral phosphodiesterase-4 inhibitor apremilast—which is also poised to enter the market in 2014—may see use in earlier lines of therapy than the emerging biologics and Xeljanz.

"Of the emerging systemic agents, the three IL-17 inhibitors—secukinumab, ixekizumab, and brodalumab—as well as MK-3222, have shown the most impressive efficacy. The efficacy of ixekizumab and brodalumab in Phase II clinical trials appears comparable to the most effective biologic for psoriasis, Janssen/Merck/Mitsubishi Tanabe's Remicade, and Phase III clinical trial data for secukinumab suggests impressive efficacy comparable to the two other agents in this drug class," said Decision Resources Business Insights Analyst Kathryn Beane. "Nevertheless, reservations about these agents' novel mechanisms of action and relatively limited safety profiles will mean that physicians will reserve these drugs initially for patients who have failed TNF-alpha inhibitors and Stelara."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
2. Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
3. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
4. AbGenomics International has raised $9.6 million for advancing its psoriasis phase-II trials in US
5. Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
6. Flu season threat greater for people with psoriasis and psoriatic arthritis who are taking immunosuppressive drugs
7. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
8. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
9. Varying Technology and Application Trends Pep up the Mature Research Antibodies Market, Finds Frost & Sullivan
10. Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
11. For Drug Manufacturers Bringing a New Product to Market, Gaining the Support of Influential Doctors Is a Mission-Critical Priority
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 In a historic vote among ... plans to construct a medical cannabis cultivation facility and dispensary on tribal ... of New York as a provider for patients in the ... York as a provider for patients in the state,s Medical ... 29% (34) to approve the project and pursue designation from the ...
(Date:2/8/2016)... , Feb. 8, 2016 ... the "Knee Reconstruction Devices Market by Product ... Implants), and Geography (U.S., Canada, Eu-5, Japan, Bric, ... 2020" report to their offering. ... of the "Knee Reconstruction Devices Market by ...
(Date:2/8/2016)... , Feb. 8, 2016  The University of ... announced today that, as part of the development ... of the first hospitals in the U.S. to start ... Muraszko , M.D., U-M,s chair of neurosurgery. ... neurosurgery. --> The BrightMatter technology from ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Brenton Engineering , powered by ... flow wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This new ... semi-automatic or fully-automatic case packing with a small footprint, rugged, highly flexible, and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local ... the greater Venice, FL area, has initiated a fundraiser for a two year ... just four days after Christmas. To support this beautiful child who is facing ...
(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's document management software has ... a cloud hosted environment for FileHold software that is pay per user subscription-based ... applications using the FileHold web services API. DocuSyst also advises clients on fully ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... speaking on how healthcare companies can use newly released government data on populations ... a population and intervene and capture the value they create to succeed in ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... women on Friday in recognition of National Wear Red Day. National Wear Red ... heart disease and stroke in women. Heart disease and stroke cause 1 in 3 ...
Breaking Medicine News(10 mins):